Observations following discontinuation of long-term denosumab therapy
Crossref DOI link: https://doi.org/10.1007/s00198-017-3919-1
Published Online: 2017-01-31
Published Print: 2017-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
McClung, M. R.
Wagman, R. B.
Miller, P. D.
Wang, A.
Lewiecki, E. M.
Funding for this research was provided by:
Amgen
License valid from 2017-01-31